Therapeutic Potential of GLP-1 Receptor Agonists for Smoking Cessation - PubMed
5 hours ago
- #smoking cessation
- #GLP-1 receptor agonists
- #nicotine addiction
- GLP-1 receptor agonists (GLP-1RA) are being studied for treating neuropsychiatric conditions, including substance use disorders like smoking.
- Cigarette smoking leads to high morbidity and mortality, partly due to increased cardiometabolic disease risk, and current cessation therapies have modest quit rates, necessitating new treatments.
- GLP-1RA show promise by modulating nicotine reward, reducing nicotine self-administration, preventing withdrawal-related hyperphagia, and potentially preventing post-cessation weight gain in early clinical trials.
- These therapies may also reduce craving and improve cessation rates, while their efficacy in cardiometabolic risk reduction enhances their appeal for smokers.
- Future research should focus on neural mechanisms, clinical subgroups (e.g., those with metabolic or psychiatric disorders), and priorities for translational studies, as highlighted in randomized trials and reviews.